Evaluation of the analytical sensitivity of ACON and LumiraDx SARS-CoV-2 rapid antigen tests using samples with presumed Omicron variant

[1]  M. Batty,et al.  Analytical Sensitivity of Lateral Flow Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75 , 2022, Journal of clinical microbiology.

[2]  I. Eckerle,et al.  Analytical Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 Variant , 2022, Microbiology spectrum.

[3]  A. Baiker,et al.  Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens , 2022, Infection.

[4]  R. Arnaout,et al.  Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron and Delta Variants of Concern Using Live-Virus Culture , 2022, Journal of clinical microbiology.

[5]  J. Dogné,et al.  Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant , 2022, Viruses.

[6]  L. Kaderali,et al.  Impaired detection of omicron by SARS-CoV-2 rapid antigen tests , 2022, Medical Microbiology and Immunology.

[7]  H. Yassine,et al.  Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines , 2022, Annals of medicine.

[8]  R. Schinazi,et al.  Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern , 2022, iScience.

[9]  M. Kamal,et al.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic , 2022, Environmental Research.

[10]  M. Batty,et al.  Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2 Omicron Variant , 2021, Journal of clinical microbiology.

[11]  A. Pandey,et al.  Analytical sensitivity and specificity of four point of care rapid antigen diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet digital PCR, and a mass spectrometric antigen assay as comparator methods. , 2021, Clinical chemistry.

[12]  J. Ruijter,et al.  Efficiency-correction is required for accurate qPCR analysis and reporting. , 2021, Clinical chemistry.

[13]  B. Hiestand,et al.  Evaluation of Performance of the BD Veritor SARS-CoV-2 Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19 , 2021, Journal of Clinical Microbiology.

[14]  P. Drain,et al.  A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study , 2021, Infectious Diseases and Therapy.

[15]  R. Orlandi,et al.  Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting , 2021, Journal of Clinical Microbiology.

[16]  J. Tate,et al.  Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[17]  N. Lennon,et al.  Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts , 2021, Journal of Clinical Microbiology.

[18]  E. Crawford,et al.  Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco , 2021, The Journal of infectious diseases.

[19]  M. Killerby,et al.  Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[20]  E. Beck,et al.  Comparison of the Quidel Sofia SARS FIA Test to the Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients , 2020, Journal of Clinical Microbiology.

[21]  A. Gayet-Ageron,et al.  Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers , 2020, medRxiv.

[22]  E. Crawford,et al.  Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco , 2020, medRxiv.

[23]  Gannon C.K. Mak,et al.  Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus , 2020, Journal of Clinical Virology.

[24]  Charles K. Cooper,et al.  Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia SARS Antigen point-of-care test. , 2020, medRxiv.

[25]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.